GBA1 and Parkinson disease: Indeed, several longitudinal investigations of GBA1 variant carriers are under way, not limited to the UK‐based RAPSODI and PD FRONTLINE study, Parkinson's Progression Markers Initiative, and active clinical trials aiming to evaluate prodromal parkinsonian features in this unique cohort (ClinicalTrials.gov Identifier: NCT05253560).